BR9812239A - Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto - Google Patents

Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto

Info

Publication number
BR9812239A
BR9812239A BR9812239-8A BR9812239A BR9812239A BR 9812239 A BR9812239 A BR 9812239A BR 9812239 A BR9812239 A BR 9812239A BR 9812239 A BR9812239 A BR 9812239A
Authority
BR
Brazil
Prior art keywords
compound
treatment
alkyl
disorders
substituted
Prior art date
Application number
BR9812239-8A
Other languages
English (en)
Inventor
Stefan Berg
Mats Linderberg
Svante Ross
Seth-Olov Thorberg
Bengt Ulff
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR9812239A publication Critical patent/BR9812239A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)

Abstract

"COMPOSTO, FORMULAçãO FARMACêUTICA, USO DO COMPOSTO, PROCESSOS PARA O TRATAMENTO DE DISTúRBIOS, PARA O TRATAMENTO DE DISTúRBIOS MEDIADOS POR 5-HIDROXITRIPTAMINA, E, PARA A PREPARAçãO DO COMPOSTO". A presente invenção refere-se a novos derivados de 3,4-dihidro-2H-1 benzopirano substituidos por piperidinila-ou piperazinila tendo a fórmula (I) em que X é N ou CH; Y é NR2CH2, CH2 NR2, NR2CO, CONR2, ou NR2SO2, em que R2 é H ou alquila C1-C6, R1 é H, alquila C1-C6, ou cicloalquila C1-C6, R3 é alquila C1-C6, cicloalquila C1-C6 ou (CH2)n-arila, em que arila é fenila ou anel heteroaromático contendo um ou mais heteroátomos selecionados dentre N,O e S e que podem ser mono- ou di-substituídos, n -e O-4, R9 é alquila C1-C6, cicloalquila C3-C6, OCF3, OCHF3, OCH2F, halogênio, CONR6R7, CN, CF3, OH, alcoxi C1-C6, NR6R7, SO3CH3, SO3CF3, SO2NR6R7, um anel heterocíclico ou heteroaromático não substituído ou substituído contendo um ou dois heteroátomos, selecionados dentre N e O, em que o(s) substituinte (s) é (são) alquila C1-C6, ou COR8, em que R6, R7, e R8 são como definidos acima, como (R enantiómeros, (S) enantiómeros, ou um racemato na forma de uma base livre ou um sal farmaceuticamente aceitável, ou solvatos do mesmo, um processo para sua preparação, composições farmacêuticas contendo referidos compostos terapeuticamente ativos, e ao uso de referidos compostos ativos em terapia.
BR9812239-8A 1997-09-18 1998-09-09 Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto BR9812239A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703378A SE9703378D0 (sv) 1997-09-18 1997-09-18 New compounds
PCT/SE1998/001604 WO1999014213A1 (en) 1997-09-18 1998-09-09 Substituted chroman derivatives

Publications (1)

Publication Number Publication Date
BR9812239A true BR9812239A (pt) 2000-07-18

Family

ID=20408298

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812239-8A BR9812239A (pt) 1997-09-18 1998-09-09 Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto

Country Status (23)

Country Link
US (2) US6387899B1 (pt)
EP (1) EP1025096B1 (pt)
JP (1) JP4002392B2 (pt)
KR (1) KR20010024078A (pt)
CN (1) CN1278809A (pt)
AR (1) AR016651A1 (pt)
AT (1) ATE255099T1 (pt)
AU (1) AU9193398A (pt)
BR (1) BR9812239A (pt)
CA (1) CA2303926A1 (pt)
DE (1) DE69820103T2 (pt)
EE (1) EE200000144A (pt)
HR (1) HRP20000133A2 (pt)
HU (1) HUP0100276A3 (pt)
IL (1) IL135074A0 (pt)
IS (1) IS5403A (pt)
NO (1) NO20001403L (pt)
PL (1) PL339661A1 (pt)
SE (1) SE9703378D0 (pt)
SK (1) SK2872000A3 (pt)
TR (1) TR200000737T2 (pt)
WO (1) WO1999014213A1 (pt)
ZA (1) ZA987806B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
CN1592745A (zh) 2001-01-16 2005-03-09 阿斯特拉曾尼卡有限公司 治疗用苯并－γ－吡喃酮化合物
JP4280067B2 (ja) 2001-01-16 2009-06-17 アストラゼネカ・アクチエボラーグ 治療用ヘテロ環式化合物
KR20030070917A (ko) * 2001-01-16 2003-09-02 아스트라제네카 아베 치료용 크로만 화합물
WO2002066454A1 (en) * 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
EP1408976B3 (en) * 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
GB0124020D0 (en) * 2001-10-05 2001-11-28 Astrazeneca Ab Chemical compounds
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
US7514461B2 (en) 2003-09-19 2009-04-07 Edison Pharmaceuticals, Inc. Chroman derivatives
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
KR100681453B1 (ko) * 2005-03-22 2007-02-12 태남자동화기기 주식회사 권종 분류 기능을 구비한 지폐 방출기
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
WO2008130319A2 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
WO2008130323A1 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel 8-piperazine-tetrahydronaphtalene derivatives for the treatment of pain
WO2008130321A2 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
WO2008130322A1 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel 5-heterocyclyl-chromane derivatives for the treatment of pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627027B2 (en) * 1989-04-27 1992-08-13 Pharmacia & Upjohn Company Substituted 3-amino chromans
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
US5972935A (en) 1995-08-11 1999-10-26 Smithkline Beecham P.L.C. Biphenyl(thio)amide and bipennylethan(thi) one derivatives, their preparation and their use as 5-HT1D receptor antagonists

Also Published As

Publication number Publication date
ATE255099T1 (de) 2003-12-15
CA2303926A1 (en) 1999-03-25
WO1999014213A1 (en) 1999-03-25
AR016651A1 (es) 2001-07-25
KR20010024078A (ko) 2001-03-26
PL339661A1 (en) 2001-01-02
US6384225B1 (en) 2002-05-07
EP1025096A1 (en) 2000-08-09
IS5403A (is) 2000-03-14
TR200000737T2 (tr) 2000-09-21
CN1278809A (zh) 2001-01-03
NO20001403D0 (no) 2000-03-17
JP4002392B2 (ja) 2007-10-31
US6387899B1 (en) 2002-05-14
ZA987806B (en) 1999-03-18
DE69820103T2 (de) 2004-09-02
SK2872000A3 (en) 2000-11-07
AU9193398A (en) 1999-04-05
EP1025096B1 (en) 2003-11-26
HUP0100276A3 (en) 2002-08-28
HRP20000133A2 (en) 2001-12-31
IL135074A0 (en) 2001-05-20
JP2001516755A (ja) 2001-10-02
EE200000144A (et) 2001-02-15
SE9703378D0 (sv) 1997-09-18
DE69820103D1 (de) 2004-01-08
NO20001403L (no) 2000-05-18
HUP0100276A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
BR9812239A (pt) Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto
YU2300A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
DK0649418T3 (da) 7-(2-aminoethyl)benzothiazolon
SE9601110D0 (sv) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
MXPA05007494A (es) Nuevos compuestos.
SE9703377D0 (sv) New compounds
NO931317L (no) Et terapeutisk middel for parkinson's sykdom
DK0748315T3 (da) Anvendelse af imidazolderivater til behandling af lidelser, der involverer angiotensinreceptorer AT1 og AT2, disse produkter, fremstilling deraf, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
JPS5598179A (en) Novel arylether*its manufacture and drug containing same for treating allergic disease
HUP0104058A2 (hu) N-diszubsztituált piperazin vagy 1,4 diszubsztituált piperidin heterociklusos származékai és ezeket tartalmazó gyógyászati készítmények
NO800447L (no) Derivater av difenylhydantoin, farmasoeytiske preparater inneholdende slike preparater, samt fremgangsmaate til fremstilling av de aktive forbindelser
ATE8144T1 (de) Indolobenzoxazine, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
DE3363553D1 (en) Substituted alpha-(ethyl)-alpha-(phenyl)-(omega-(dialkylamino)-alkoxy)-benzyl alcohols, their acid addition salts and quaternary salts, process for their preparation, as well as medicines containing these compounds
ATE11915T1 (de) Benzothiazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung.
MX9405111A (es) Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina).
NO150436C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenylamino-imidazolin-derivater
DK1161424T3 (da) Hidtil ukendte diazolderivater som serotonerge midler
ES8600224A1 (es) Procedimiento de preparacion de nuevos derivados carbamiloxibenzoles
SE7403176L (pt)
HU896174D0 (en) Process for the preparation of heterocyclic derivatives fusionated 1,2,3,4-tetrahydro-acridine and pharmaceutical compositions thereof
JPS55162785A (en) Novel xanthine derivative* its manufacture and allurgy therapeutic agent containing same
HUP0401038A2 (hu) Piperazinilkarbonilkinolinok és -izokinolinok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE3977T1 (de) Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
IL97611A (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.